Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR7390 + SHR-1210 + SHR3162
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SHR7390 + SHR-1210 + SHR3162 is an investigational combination regimen for advanced solid tumors, particularly evaluated in colorectal cancer and other solid tumors. This triple therapy combines: - **SHR7390**: a small molecule inhibitor of MEK1/2 kinases involved in the MAPK signaling pathway, aiming to reduce tumor cell proliferation. - **SHR-1210** (camrelizumab): a humanized anti-PD-1 monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) receptor, promoting T-cell-mediated immune response against tumors. - **SHR3162** (fuzuloparib): a small molecule PARP inhibitor targeting DNA repair in tumor cells, enhancing tumor cell death, particularly in those with BRCA mutations. The regimen was developed and tested by Jiangsu Hengrui Medicine for advanced solid tumors in early-phase clinical trials to assess safety, tolerability, and preliminary anti-tumor activity[1][3][5][6][7].
- Brand names
- AiRuiKaAiRuiYi
- Other names
- camrelizumabfuzuloparib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SHR7390 + SHR-1210 + SHR3162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR7390 + SHR-1210 + SHR3162.